LBBS.AOS.01: Late-Breaking Basic Science: Exploring New Therapeutic Horizons for Cardiometabolic Disease: Before Phase 0

Saturday, November 16, 2024, 1:30 PM-2:15PM

• A Novel CRISPR based Epigenetic Silencer Potently, Durably, and Safely Reduces LDLc in Non-Human Primates at Therapeutically Relevant Doses
• Cellularized Tissue-Engineered Biological Ventricular Assist Devices Improve Global Cardiac Function in a Porcine Model of Ischemic Cardiomyopathy
• Pan-EphB tyrosine kinase inhibitors in obesity and associated metabolic diseases.
• Biodistribution of Systemically Administered Lab-grown, 3D Extracellular Matrix Particles and Their Effects on Post-Myocardial Infarction Cardiac Function
• Combination Therapy with Semaglutide and Inclisiran Reduces Synergisstically Anthracycline-Induced Cardiotoxicity under Hyperlipidemia: New Evidences in Prevention of CTRCD in Cancer Patients

LBBS.AOS.02: Late-Breaking Basic Science: Novel Mechanisms in Cardiac Pathophysiology

Sunday, November 17, 2024, 8:00 AM-9:15 AM

• The chiral nematic pattern underlies cardiac tissue organization and function
• T-cadherin Mediated Increased Uptake of Dysfunctional Adipocytes Derived Small Extracellular Vesicles by Cardiomyocyte as a Novel Mechanisms Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice
• Dual inhibition of PDE5-mTOR Enhances Chemoimmunotherapeutic Efficacy in Breast Cancer and Reduces Cardiotoxicity
• Novel REV-ERBα/β agonist Ameliorates Heart Failure Induced by Pressure Overload in Mice by Suppressing Aberrant Gene Expression
• The chiral nematic pattern underlies cardiac tissue organization and function (Accepted, not confirmed at time of publication)
• Sex-dependent Changes in Extracellular Matrix Remodeling in the Murine Heart Following Myocardial Infarction

LBBS.APS.01: Late-Breaking Basic Science: New Insights in Cardiovascular Health and Disease

Saturday, November 16, 2024, 10:30 AM - 11:15 AM

• TRPV4 as a Potential Therapeutic Target for Right Ventricular Failure Secondary to Pulmonary Hypertension
• Impact of Genetic Factors on Antioxidant Rescue of Maternal Diabetes-Associated Congenital Heart Disease
• Novel mechanistic insights into the role for EGLN3 in stabilizing atherosclerotic plaques
• Pro-angiogenic Effects of Cardiac Macrophages Enhance Myocardial Repair in Regenerative Species
• Chemotherapy Induced Cardiotoxicity Analysis of Oxaliplatin on Human Heart Organoids Using Optical Coherence Tomography
• Association of Oxidatively Damaged Mitochondrial Proteins in Adipocyte-Derived Extracellular Vesicles with Heart Failure with Preserved Ejection Fraction in Type 2 Diabetes Patients
• Chronic administration of the polyamine spermine effectively prolongs the QT interval and prevents life-threatening arrhythmias in a mouse model of Short QT Syndrome Type 3
• Maternal Diabetes Induces Heterotaxy Syndrome by Lowering Intracellular pH in Mice Embryos
• Nonviral, Ultrasound Mediated Gene Delivery to the Heart of Mice and Macaques
• Cellular retention of growth arrest specific protein 6 (GAS6) accelerates calcification of aortic valves
• Impact of Prediabetes-Related Pancreatic Hypersecretion of Amylin on Cardiac Metabolism
• Central Glucagon-like Peptide-2 Receptor and Melanocortin 4 Receptor Mediate the Mobilization of Intestinally Stored Lipids by Glucagon-like Peptide-2
• Distinct Metabolomic Changes Associated with Human End-Stage Ischemic and Non-Ischemic Cardiomyopathy
• VAMP8 Deletion Mitigates Atherosclerosis by Modulating Platelet Inflammatory Cargo Release
• Obstructive Sleep Apnea Suppresses Cholesterol Efflux in Endothelial Cells
• A Novel Subcellular β-arrestin Biased Allosteric Modulator (Accepted, not confirmed at time of publication)
• Myeloid Specific S100A12 aggravated the atherosclerotic lesion by promoting PDCD4 upregulation (Accepted, not confirmed at time of publication)
• Sex, Hormones and Arrhythmias: Sex-Specific Risks for Sinus Tachycardias and Atrial Fibrillation
• Weight Loss Independent Benefits of the GLP-1 Receptor Agonist Semaglutide in Cardiometabolic HFpEF
• Direct Comparison of Mechanical Circulatory Support Devices in a Porcine Model of Myocardial Infarction Complicated by Acute Mitral Regurgitation and Cardiogenic Shock
• Acellular Tissue Engineered Vessels as Conduits for Coronary Artery Bypass Grafting
• Nicotinamide Riboside Preserves Systolic Function in a Swine Model of Heart Failure
• Development of Acute Large Animal Model of Heart Failure with Preserved Ejection Fraction (Accepted, not confirmed at time of publication)
• Tertiary Lymphoid Organs as a Sign of Chronic Inflammation in Atherosclerotic Coronary Atheromas
• Tryptophan-derived 3-Hydroxyanthranilic Acid Promotes Angiogenesis in Mouse Ischemic Hindlimbs
• Genomic and Single-Cell Transcriptomic Profiling of Calcific Aortic Valve Disease: A Multi-Center Cohort Study (Accepted, not confirmed at time of publication)
• miR-146a Deficiency Ablates Thoracic Aortic Aneurysmal Rupture in Mice
• RKER-012, A Novel Modified ActRIIB Ligand Trap, Reversed Experimental Pulmonary Arterial Hypertension (Accepted, not confirmed at time of publication)
• Endothelial Dysfunction due to CAV-1 Depletion links Atrial Fibrillation and Cognitive Decline

Abstracts and presentations are embargoed for release until the date and time of presentation at Scientific Sessions 2024. Information may not be released before then. Failure to honor embargo policies will result in the trial being withdrawn on site and barred from presentation. Any breach of the embargo policy may adversely affect participation in future AHA Sessions. Clinical trial sponsors must comply with the embargo guidelines established by the American Heart Association.

We understand that the sponsoring organization may be required to release top-line results in order to follow SEC (Security Exchange Commission) regulations, however, AHA must be notified before ANY release of information. Any level of information released without approval will be considered an embargo break. Please contact Mary Lu Hare if you are preparing a press release or for any questions.